SALBUTAMOL ATTENUATES THE ARRHYTHMOGENIC EFFECT OF AMINOPHYLLINE IN CARDIAC ORGANOIDS EXPERIMENTAL MODEL (AFM Bio Med 2025)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F25%3A00141210" target="_blank" >RIV/00216224:14110/25:00141210 - isvavai.cz</a>

Výsledek na webu

<a href="https://afmbiomed.org/Data/Sites/1/barcelona2025/libro-abstracts-afbiomed-2025_compressed-2_compressed.pdf" target="_blank" >https://afmbiomed.org/Data/Sites/1/barcelona2025/libro-abstracts-afbiomed-2025_compressed-2_compressed.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

SALBUTAMOL ATTENUATES THE ARRHYTHMOGENIC EFFECT OF AMINOPHYLLINE IN CARDIAC ORGANOIDS EXPERIMENTAL MODEL (AFM Bio Med 2025)

Popis výsledku v původním jazyce

The aminophylline-salbutamol combination is widely implemented in clinical settings for the management of obstructive pulmonary disease. While the adverse effects, including arrhythmogenicity, of each bronchodilator are well-documented, the arrhythmogenic potential of their combined use remains largely uncharacterized. This study [1] aimed to delineate the proarrhythmic risk associated with aminophylline and salbutamol co-administration in vitro. Atomic force microscopy (AFM) coupled with cardiac organoids derived from human pluripotent stem cells (hPSC-CMs) was employed as previously described [2,3]. We assessed the chronotropic, inotropic, and arrhythmogenic responses of hPSC-CMs as reviewed [4]. Screened were responses to salbutamol monotherapy and aminophylline-salbutamol co-treatment. Heart rate variability (HRV) and beat rate variability (BRV) analyses enabled the detection of arrhythmic events in AFM-based hPSC-CM recordings. Results demonstrated a synergistic chronotropic and inotropic effect with combination therapy versus monotherapy. Crucially, salbutamol attenuated aminophylline’s arrhythmogenic impact, likely through endothelial nitric oxide synthase activation mediated by beta-2 adrenergic receptor engagement. Findings were corroborated across two hPSC-CM lines (CCTL4 and CCTL12), indicating that salbutamol may confer cardiovascular protection when co-administered with aminophylline by mitigating its arrhythmogenic potential, in addition to providing bronchodilation.

Název v anglickém jazyce

SALBUTAMOL ATTENUATES THE ARRHYTHMOGENIC EFFECT OF AMINOPHYLLINE IN CARDIAC ORGANOIDS EXPERIMENTAL MODEL (AFM Bio Med 2025)

Popis výsledku anglicky

The aminophylline-salbutamol combination is widely implemented in clinical settings for the management of obstructive pulmonary disease. While the adverse effects, including arrhythmogenicity, of each bronchodilator are well-documented, the arrhythmogenic potential of their combined use remains largely uncharacterized. This study [1] aimed to delineate the proarrhythmic risk associated with aminophylline and salbutamol co-administration in vitro. Atomic force microscopy (AFM) coupled with cardiac organoids derived from human pluripotent stem cells (hPSC-CMs) was employed as previously described [2,3]. We assessed the chronotropic, inotropic, and arrhythmogenic responses of hPSC-CMs as reviewed [4]. Screened were responses to salbutamol monotherapy and aminophylline-salbutamol co-treatment. Heart rate variability (HRV) and beat rate variability (BRV) analyses enabled the detection of arrhythmic events in AFM-based hPSC-CM recordings. Results demonstrated a synergistic chronotropic and inotropic effect with combination therapy versus monotherapy. Crucially, salbutamol attenuated aminophylline’s arrhythmogenic impact, likely through endothelial nitric oxide synthase activation mediated by beta-2 adrenergic receptor engagement. Findings were corroborated across two hPSC-CM lines (CCTL4 and CCTL12), indicating that salbutamol may confer cardiovascular protection when co-administered with aminophylline by mitigating its arrhythmogenic potential, in addition to providing bronchodilation.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

<a href="/cs/project/LX22NPO5104" target="_blank" >LX22NPO5104: Národní institut pro výzkum metabolických a kardiovaskulárních onemocnění</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů